R&D
R&D

Project Overview

AnaMar AB has invented, and is developing a portfolio of novel high affinity, highly selective peripherally acting 5-HT2B receptor antagonists with potential use in a wide range of human diseases, based on the receptor’s significant role in a variety of pathological mechanisms.

Candidate Drug AM1476

AnaMar’s current focus is on fibrotic indications and AnaMar operations are primarily concentrated on developing the candidate drug AM1476 for the treatment of the orphan indication systemic sclerosis. AM1476 is in late preclinical phase on track for CTA/IND submission.

Read more >>

New Project Opportunities

5-HT and specifically the 5-HT2B receptor has a well-known involvement in diseases associated with fibrosis, inflammation, pain, vascular tonus and cell proliferation, and AnaMar is actively searching for collaborations in such indications.

Read more >>